Pecora P G, Kaplan B
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh Medical Center, PA, USA.
Ann Pharmacother. 1996 Jul-Aug;30(7-8):870-2. doi: 10.1177/106002809603000729.
The literature presented supports a small but highly probable association between corticosteroids and ulcers. The following characteristics appear to be exhibited by patients who are at high risk for developing corticosteroid-induced ulcers: corticosteroids coadministered with NSAIDs, a total dosage greater than 1000 mg of prednisone equivalent, a duration of therapy longer than 30 days, and a history of PUD. Further prospective research examining the association of corticosteroids and PUD in conjunction with other contributing factors is needed. The role of prophylactic therapy to prevent corticosteroid-induced ulcers is not well established. Even though a small study in liver transplant recipients, who are already at increased risk for GI ulceration, has suggested beneficial effects with prophylactic regimens, generalization of these results to all corticosteroid-treated patients would be inappropriate. Large prospective trials to determine the most efficacious prophylactic regimen (e.g., histamine2-receptor antagonists, proton pump inhibitors, cytoprotective agents [misoprostol]) for corticosteroid-induced ulcerations are not currently available. We suggest that most prophylaxis currently performed is unnecessary. In high-risk patients, however, prophylaxis appears to be prudent until further information is available.
现有文献表明,皮质类固醇与溃疡之间存在一种虽小但极有可能的关联。出现皮质类固醇诱导性溃疡高风险的患者似乎具有以下特征:皮质类固醇与非甾体抗炎药联合使用、总剂量大于1000毫克泼尼松等效剂量、治疗持续时间超过30天以及有消化性溃疡病史。需要进一步开展前瞻性研究,以检验皮质类固醇与消化性溃疡以及其他相关因素之间的关联。预防皮质类固醇诱导性溃疡的治疗作用尚未明确。尽管一项针对肝移植受者(他们本身发生胃肠道溃疡的风险就更高)的小型研究表明预防性治疗方案具有有益效果,但将这些结果推广至所有接受皮质类固醇治疗的患者是不合适的。目前尚无大型前瞻性试验来确定针对皮质类固醇诱导性溃疡最有效的预防方案(例如组胺2受体拮抗剂、质子泵抑制剂、细胞保护剂[米索前列醇])。我们认为目前大多数预防性治疗是不必要的。然而,在有高风险的患者中,在获得更多信息之前,进行预防似乎是审慎之举。